Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
Critical Care2014Vol. 18(1), pp. R3–R3
Citations Over TimeTop 1% of 2014 papers
Katherine Chang, Catherine Svabek, Cristina Vazquez Guillamet, Bryan Sato, David Rasche, Strother Wilson, Paul F. Robbins, Nancy D. Ulbrandt, JoAnn Suzich, Jonathan M. Green, Andriani C. Patera, Wade Blair, Subramaniam Krishnan, Richard S. Hotchkiss
Abstract
In vitro blockade of the PD-1:PD-L1 pathway decreases apoptosis and improves immune cell function in septic patients. The current results together with multiple positive studies of anti-PD-1 and anti-PD-L1 in animal models of bacterial and fungal infections and the relative safety profile of anti-PD-1/anti-PD-L1 in human oncology trials to date strongly support the initiation of clinical trials testing these antibodies in sepsis, a disorder with a high mortality.
Related Papers
- → Evaluation of updated sepsis scoring systems and systemic inflammatory response syndrome criteria and their association with sepsis in equine neonates(2018)83 cited
- → A systematic investigation on animal models of cyclosporine A combined with Escherichia coli to simulate the immunosuppressive status of sepsis patients before onset(2018)8 cited
- → Correlation of Clinical Sepsis Definitions with Microbiological Characteristics in Patients Admitted Through a Sepsis Alert System; A Prospective Cohort Study(2021)1 cited
- → Sepsis-3-the use of sepsis in children: we still have a lot of work to do(2017)
- → Sepsis(2017)